The US Centers for Disease Control and Prevention (ACIP) Advisory Committee concluded that there is a “possible link” between COVID-19 mRNA vaccines (Pfizer / BioNTech and Moderna) and cases of myocardial infarction and myocarditis.
The incidence is higher in young people, mainly in men, and more often occurs a few days after the second vaccination.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the heart membrane. Symptoms associated with diagnoses include chest pain, shortness of breath, and a feeling of a rapid heartbeat or throbbing in the chest. In most cases, the disease is treated with a number of non-steroidal (or steroidal) anti-inflammatory drugs. Most of the patients recovered completely.
“The clinical picture of cases myocarditis after vaccination was clear, most often within a week of the second dose, with chest pain being the most common symptom, ”said Dr. Grace Lee, president of ACIP.
According to Tom Shimabukuro, deputy director of the CDC’s Directorate of Immune Safety, the agency has received reports of 1,226 cases of myocarditis, of which 827 (or 67.5%) occurred after the second dose of the mRNA vaccine. This is about 12.6 cases per million doses administered (approximately one in 80,000). Of the 1226 patients, 484 were under 29 years of age, two-thirds were men.
FDA to add warning to newsletters about these vaccines, and medical experts will find out why these side effects occur.
With schools fully reopening in the fall, federal, state and local officials are pushing the FDA to approve a vaccine for children under 12. However, scientists have drawn attention that data on the safety of vaccines for younger age groups are insufficient, and they require more careful study.
According to the ACIP report of June 11, 2021, where cases were disaggregated by age group, 79 cases of myocarditis or pericarditis were reported through the vaccine adverse reaction reporting system between the ages of 16 and 17 who received 2.3 million doses.
This is much higher than the expected 2 to 19 cases. 18-24-year-olds who received 9.8 million doses reported 196 cases of myocarditis and pericarditis, compared with the expected 8-83 cases.